Deciphering the structure and mechanism-of-action of computer-designed mastoparan peptides.

AMPs bacterial infections mastoparan selectivity structural biology

Journal

The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646

Informations de publication

Date de publication:
24 Nov 2023
Historique:
revised: 05 10 2023
received: 24 05 2023
accepted: 08 11 2023
medline: 24 11 2023
pubmed: 24 11 2023
entrez: 24 11 2023
Statut: aheadofprint

Résumé

Mastoparans are cationic peptides with multifunctional pharmacological properties. Mastoparans-R1 and R4 were computationally designed based on native mastoparan-L from wasps and have improved therapeutic potential for the control of bacterial infections. Here, we evaluated whether these peptides maintain their activity against Escherichia coli strains under a range of salt concentrations. We found that mastoparans R1 and R4 preserved their activity under the conditions tested, including having antibacterial activities at physiological salt concentrations. The overall structure of the peptides was investigated using circular dichroism spectroscopy in a range of solvents. No significant changes in secondary structure were observed (random coil in aqueous solutions and α-helix in hydrophobic and anionic environments). The three-dimensional structures of mastoparan-R1 and R4 were elucidated through nuclear magnetic resonance spectroscopy, revealing amphipathic α-helical segments for Leu3-Ile13 (mastoparan-R1) and Leu3-Ile14 (mastoparan-R4). Possible membrane-association mechanisms for mastoparan-R1 and R4 were investigated through surface plasmon resonance and leakage studies with synthetic POPC and POPC/POPG (4:1) lipid bilayers. Mastoparan-L had the highest affinity for both membrane systems, whereas the two analogs had weaker association, but improved selectivity for lysing anionic membranes. This finding was also supported by molecular dynamics simulations, in which mastoparan-R1 and R4 were found to have greater interactions with bacteria-like membranes compared to model mammalian membranes. Despite having a few differences in their functional and structural profiles, the mastoparan-R1 analog stood out with the highest activity, greater bacteriostatic potential, and selectivity for lysing anionic membranes. This study reinforces the potential of mastoparan-R1 as a drug candidate.

Identifiants

pubmed: 37997610
doi: 10.1111/febs.17010
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

This article is protected by copyright. All rights reserved.

Auteurs

Karen G N Oshiro (KGN)

Programa de Pós-Graduação em Patologia Molecular, Faculdade de Medicina, Universidade de Brasília, Brasília/DF, 70910900, Brazil.
S-inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande/MS, 79117900, Brazil.
Centro de Análises Proteômicas e Bioquímicas, Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília/DF, 70790160, Brazil.

Carlos D P Freitas (CDP)

Laboratório de RMN, Instituto de Química, Universidade Federal de Goiás, Goiânia/GO, 74690900, Brazil.

Samilla B Rezende (SB)

S-inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande/MS, 79117900, Brazil.
Centro de Análises Proteômicas e Bioquímicas, Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília/DF, 70790160, Brazil.

Raquel M Q Orozco (RMQ)

S-inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande/MS, 79117900, Brazil.
Centro de Análises Proteômicas e Bioquímicas, Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília/DF, 70790160, Brazil.

Lai Y Chan (LY)

Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for, Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia.

Nicole Lawrence (N)

Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for, Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia.

Luciano M Lião (LM)

Laboratório de RMN, Instituto de Química, Universidade Federal de Goiás, Goiânia/GO, 74690900, Brazil.

Maria L R Macedo (MLR)

Laboratório de Purificação de Proteínas e suas Funções Biológicas, Universidade Federal de Mato Grosso do Sul, Campo Grande/MS, 79070900, Brazil.

David J Craik (DJ)

Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for, Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia.

Marlon H Cardoso (MH)

Programa de Pós-Graduação em Patologia Molecular, Faculdade de Medicina, Universidade de Brasília, Brasília/DF, 70910900, Brazil.
S-inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande/MS, 79117900, Brazil.
Centro de Análises Proteômicas e Bioquímicas, Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília/DF, 70790160, Brazil.
Laboratório de Purificação de Proteínas e suas Funções Biológicas, Universidade Federal de Mato Grosso do Sul, Campo Grande/MS, 79070900, Brazil.

Octávio L Franco (OL)

Programa de Pós-Graduação em Patologia Molecular, Faculdade de Medicina, Universidade de Brasília, Brasília/DF, 70910900, Brazil.
S-inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande/MS, 79117900, Brazil.
Centro de Análises Proteômicas e Bioquímicas, Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília/DF, 70790160, Brazil.

Classifications MeSH